表紙
市場調查報告書

臨床生物標記的全球市場 - 分析與預測:2019年∼2029年

Global Clinical Biomarkers Market: Focus on Product, Technology, End User, Clinical Area, Region, and Competitive Landscape - Analysis and Forecast, 2019-2029

出版商 BIS Research Inc. 商品編碼 931359
出版日期 內容資訊 英文 213 Pages
商品交期: 最快1-2個工作天內
價格
臨床生物標記的全球市場 - 分析與預測:2019年∼2029年 Global Clinical Biomarkers Market: Focus on Product, Technology, End User, Clinical Area, Region, and Competitive Landscape - Analysis and Forecast, 2019-2029
出版日期: 2020年03月31日內容資訊: 英文 213 Pages
簡介

全球臨床生物標記市場預測將從2018年的160億1000萬美元,到2029年達到459億1000萬美元,2019年∼2029年預計將以年複合成長率10.07%的速度成長。全球臨床生物標記市場成長,由於感染疾病的盛行率增加,個人化醫療的採用增加,生物標記的研究開發計劃的關注高漲,非侵入性診斷的需求增加而預計受到促進。

本報告提供全球臨床生物標記市場相關調查分析,市場概要,市場動態,競爭情形,市場分析與預測,主要企業等相關的系統性資訊。

目錄

摘要整理

第1章 產品定義

第2章 市場範圍

第3章 調查手法

第4章 市場概要

  • 簡介
  • 精密醫療的臨床生物標記的方法
  • 市場上可取得的臨床生物標記
  • 全球足跡

第5章 全球臨床生物標記市場:市場動態

  • 概要
  • 影響分析
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第6章 競爭情形

  • 主要策略與開發
  • 市場佔有率分析
  • 成長佔有率分析 (機會製圖)
    • 各企業

第7章 全球臨床生物標記市場:各類型

  • 診斷生物標記
  • 預測生物標記
  • 預後生物標記

第8章 全球臨床生物標記市場:各臨床領域

  • 癌症生物標記
    • 乳癌生物標記
    • 肺癌症生物標記
    • 大腸癌症生物標記
    • 前列腺癌症生物標記
  • 心臟生物標記
  • 神經生物標記
  • 感染疾病
  • 免疫生物標記
  • 新型產前診斷 (NIPT)
  • 其他

第9章 全球臨床生物標記市場:各技術

  • 即時PCR
  • 酵素免疫吸附法 (ELISA)
  • 免疫組織化學 (IHC)
  • 次世代定序 (NGS)
  • 其他

第10章 全球臨床生物標記市場:各終端用戶

  • 概要
  • 研究、學術機構
  • 生物醫藥品、生物科技企業
  • 診斷中心
  • 其他

第11章 全球臨床生物標記市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他地區

第12章 企業簡介

  • 概要
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ALCEDIAG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE N.V.
  • F. Hoffmann-La Roche Ltd.
  • Enzo Biochem Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Quest Diagnostics Incorporated
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
目錄
Product Code: BH188A

Global Clinical Biomarkers Market to Reach $45.91 Billion by 2029

Global clinical biomarkers market analysis by BIS Research projects the market to grow at a significant CAGR of 10.07% during the forecast period, 2019-2029. Global clinical biomarkers market generated $16.01 billion revenue in 2018, in terms of value.

The growth in global clinical biomarkers market is anticipated to be driven by increasing prevalence of infectious diseases, increase in adoption of personalized medicine, growing focus on biomarker research and development programs and rising demand for non-invasive diagnosis. However, there are potential restraining factors hindering the growth of the market. These factors include uncertain reimbursement policies pertaining to clinical biomarkers-based products, requirement of high capital investment, and issues related to clinical validity of biomarkers.

Expert Quote

"Efficient translation of MS-based biomarker discovery research into the development of routine clinical diagnostic assays is an important challenge in the field of personalized medicine."

Scope of the Market Intelligence on Global Clinical Biomarkers Market

Global clinical biomarkers market research provides a holistic view of the market in terms of various factors influencing it, including strategic developments and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the industrial and biological research. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global clinical biomarkers market.

Market Segmentation

Global clinical biomarkers market (on the basis of type) is segmented into diagnostic, prognostic and predictive biomarkers.

Global clinical biomarkers market (on the basis of clinical area) is segmented into cancer biomarkers, cardiac biomarkers, neurological biomarkers, infectious disease, immunological biomarkers, non-invasive prenatal testing and other clinical areas.

Global clinical biomarkers market (on the basis of technology) is segmented into real-time polymerase chain reaction, next-generation sequencing, Enzyme-linked immunosorbent assay (ELISA), and other technologies.

Global clinical biomarkers market (on the basis of end user) is segmented into research and academic laboratories, diagnostic centers, biopharmaceutical and biotech companies and other end users.

Key companies in the Global Clinical Biomarkers Market

The report also comprises 15 detailed company profiles including several key players, such as Abbott Laboratories, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Myriad Genetics, Hologic, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Enzo Biochem Inc., Centogene N.V., ALCEDIAG, and Quest Diagnostics Incorporated.

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of Work
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Clinical Biomarkers Market: Research Methodology
  • 3.2 Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Introduction
  • 4.2 Clinical Biomarkers Approaches in Precision Medicine
  • 4.3 Market Available Clinical Biomarkers
  • 4.4 Global Footprint

5 Global Clinical Biomarkers Market: Market Dynamics

  • 5.1 Overview
  • 5.2 Impact Analysis
  • 5.3 Market Drivers
    • 5.3.1 Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
    • 5.3.2 Increase in Adoption of Personalized Medicine
    • 5.3.3 Growing Focus on Biomarkers Research and Development Programs
    • 5.3.4 Rising Demand for Non-Invasive Diagnosis
  • 5.4 Market Restraints
    • 5.4.1 Uncertain Reimbursement Policies Pertaining to Clinical Biomarkers
    • 5.4.2 Requirement of High Capital Investment Hindering Expansion
    • 5.4.3 Issues Related to Clinical Validity of Biomarkers-Based Tests
  • 5.5 Market Opportunities
    • 5.5.1 Massive Scope for Adoption of Clinical Biomarkers in Emerging Nations
    • 5.5.2 Technological Advancements in Clinical Biomarkers-Based Tests
    • 5.5.3 Increased Use of Clinical Biomarkers in Widespread Applications

6 Competitive Landscape

  • 6.1 Key Strategies and Developments
    • 6.1.1 Synergistic Activities
    • 6.1.2 Product Approvals
    • 6.1.3 Product Launches and Upgradations
    • 6.1.4 Mergers and Acquisitions
    • 6.1.5 Funding and Expansion
  • 6.2 Market Share Analysis
  • 6.3 Growth Share Analysis (Opportunity Mapping)
    • 6.3.1 By Company

7 Global Clinical Biomarkers Market (by Type), 2018-2029

  • 7.1 Diagnostic Biomarkers
  • 7.2 Predictive Biomarkers
  • 7.3 Prognostic Biomarkers

8 Global Clinical Biomarkers Market (by Clinical Area), 2018-2029

  • 8.1 Cancer Biomarkers
    • 8.1.1 Breast Cancer Biomarkers
    • 8.1.2 Lung Cancer Biomarkers
    • 8.1.3 Colorectal Cancer Biomarkers
    • 8.1.4 Prostate Cancer Biomarkers
  • 8.2 Cardiac Biomarkers
  • 8.3 Neurological Biomarkers
  • 8.4 Infectious Disease
  • 8.5 Immunological Biomarkers
  • 8.6 Non-Invasive Prenatal Testing
  • 8.7 Other Clinical Areas

9 Global Clinical Biomarkers Market (by Technology), 2018-2029

  • 9.1 Real-Time PCR
  • 9.2 Enzyme-Linked Immuno Sorbent Assay (ELISA)
  • 9.3 Immunohistochemistry (IHC)
  • 9.4 Next-Generation Sequencing (NGS)
  • 9.5 Other Technologies

10 Global Clinical Biomarkers Market (by End User), 2018-2029

  • 10.1 Overview
  • 10.2 Research and Academic Laboratories
  • 10.3 Biopharmaceutical and Biotech Companies
  • 10.4 Diagnostic Centers
  • 10.5 Other End Users

11 Global Clinical Biomarkers Market (by Region), 2018-2029

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 U.K.
    • 11.3.3 France
    • 11.3.4 Italy
    • 11.3.5 Spain
    • 11.3.6 Rest-of-Europe
  • 11.4 Asia-Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 Singapore
    • 11.4.6 Rest-of-APAC
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest-of-Latin America
  • 11.6 Rest-of-the-World

12 Company Profiles

  • 12.1 Overview
  • 12.2 Abbott Laboratories
    • 12.2.1 Company Overview
    • 12.2.2 Role of Abbott Laboratories plc in the Global Clinical Biomarkers Market
    • 12.2.3 Financials
    • 12.2.4 Key Insights about Financial Health of the Company
    • 12.2.5 SWOT Analysis
  • 12.3 Agilent Technologies, Inc.
    • 12.3.1 Company Overview
    • 12.3.2 Role of Agilent Technologies, Inc. in the Global Clinical Biomarkers Market
    • 12.3.3 Financials
    • 12.3.4 Key Insights about Financial Health of the Company
    • 12.3.5 SWOT Analysis
  • 12.4 ALCEDIAG
    • 12.4.1 Company Overview
    • 12.4.2 Role of ALCEDIAG in Global Clinical Biomarkers Market
    • 12.4.3 SWOT Analysis
  • 12.5 Becton, Dickinson and Company
    • 12.5.1 Company Overview
    • 12.5.2 Role of Becton, Dickinson and Company in the Global Clinical Biomarkers Market
    • 12.5.3 Financials
    • 12.5.4 Key Insights about Financial Health of the Company
    • 12.5.5 SWOT Analysis
  • 12.6 bioMerieux S.A.
    • 12.6.1 Company Overview
    • 12.6.2 Role of bioMerieux S.A. in the Global Clinical Biomarkers Market
    • 12.6.3 Financials
    • 12.6.4 Key Insights about Financial Health of the Company
    • 12.6.5 SWOT Analysis
  • 12.7 Bio-Rad Laboratories, Inc.
    • 12.7.1 Company Overview
    • 12.7.2 Role of Bio-Rad Laboratories, Inc. in the Global Clinical Biomarkers Market
    • 12.7.3 Financials
    • 12.7.4 Key Insights about Financial Health of the Company
    • 12.7.5 SWOT Analysis
  • 12.8 CENTOGENE N.V.
    • 12.8.1 Company Overview
    • 12.8.2 Role of CENTOGENE N.V. in the Global Clinical Biomarkers Market
    • 12.8.3 Financials
    • 12.8.4 Key Insights about Financial Health of the Company
    • 12.8.5 SWOT Analysis
  • 12.9 F. Hoffmann-La Roche Ltd.
    • 12.9.1 Company Overview
    • 12.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Clinical Biomarkers Market
    • 12.9.3 Financials
    • 12.9.4 Key Insights about Financial Health of the Company
    • 12.9.5 SWOT Analysis
  • 12.10 Enzo Biochem Inc.
    • 12.10.1 Company Overview
    • 12.10.2 Role of Enzo Biochem Inc. in the Global Clinical Biomarkers Market
    • 12.10.3 Financials
    • 12.10.4 Key Insights about Financial Health of the Company
    • 12.10.5 SWOT Analysis
  • 12.11 Hologic, Inc.
    • 12.11.1 Company Overview
    • 12.11.2 Role of Hologic, Inc. in the Global Clinical Biomarkers Market
    • 12.11.3 Financials
    • 12.11.4 Key Insights about Financial Health of the Company
    • 12.11.5 SWOT Analysis
  • 12.12 Illumina, Inc.
    • 12.12.1 Company Overview
    • 12.12.2 Role of Illumina, Inc. in the Global Clinical Biomarkers Market
    • 12.12.3 Financials
    • 12.12.4 Key Insights about Financial Health of the Company
    • 12.12.5 SWOT Analysis
  • 12.13 Myriad Genetics, Inc.
    • 12.13.1 Company Overview
    • 12.13.2 Role of Myriad Genetics, Inc. in the Global Clinical Biomarkers Market
    • 12.13.3 Financials
    • 12.13.4 Key Insights about Financial Health of the Company
    • 12.13.5 SWOT Analysis
  • 12.14 Quest Diagnostics Incorporated
    • 12.14.1 Company Overview
    • 12.14.2 Role of Quest Diagnostics Incorporated in the Global Clinical Biomarkers Market
    • 12.14.3 Financials
    • 12.14.4 SWOT Analysis
  • 12.15 QIAGEN N.V.
    • 12.15.1 Company Overview
    • 12.15.2 Role of QIAGEN N.V. plc in the Global Clinical Biomarkers Market
    • 12.15.3 Financials
    • 12.15.4 Key Insights about Financial Health of the Company
    • 12.15.5 SWOT Analysis
  • 12.16 Thermo Fisher Scientific Inc.
    • 12.16.1 Company Overview
    • 12.16.2 Role of Thermo Fisher Scientific in the Global Clinical Biomarkers Market
    • 12.16.3 Financials
    • 12.16.4 Key Insights about Financial Health of the Company
    • 12.16.5 SWOT Analysis

List of Tables

  • Table 4.1: Key Commercialized Products Offered by Major Market Players
  • Table 5.1: Impact Analysis of Market Drivers
  • Table 5.2: Impact Analysis of Market Restraints
  • Table 8.1: Key Cancer Biomarkers Products Offered by Major Market Players
  • Table 8.2: Key Cancer Biomarkers Products Offered by Major Market Players
  • Table 8.3: Key Lung Cancer Biomarkers Products Offered by Major Market Players
  • Table 8.4: Key Colorectal Cancer Biomarkers Products Offered by Major Market Players
  • Table 8.5: Key Prostate Cancer Biomarkers Products Offered by Major Market Players
  • Table 8.6: Key Cardiac Biomarkers Products Offered by Major Market Players
  • Table 8.7: Key Neurological Biomarkers Products Offered by Major Market Players
  • Table 8.8: Key Infectious Disease Biomarkers Products Offered by Major Market Players
  • Table 8.9: Key Immunological Biomarkers Products Offered by Major Market Players
  • Table 8.10: Key Immunological Biomarkers Products Offered by Major Market Players
  • Table 8.11: Key Immunological Biomarkers Products Offered by Major Market Players
  • Table 9.1: Key RT-PCR-Based Biomarkers Products Offered by Major Market Players
  • Table 9.2: Key ELISA-Based Biomarkers Products Offered by Major Market Players
  • Table 9.3: Key IHC-Based Biomarkers Products Offered by Major Market Players
  • Table 9.4: Key NGS-Based Biomarkers Products Offered by Major Market Players
  • Table 9.5: Other Technologies-Based Biomarkers Products Offered by Major Market Players

List of Figures

  • Figure 1: Total Global Disease Burden by Cause, 2017
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Clinical Biomarkers Market
  • Figure 3: Share of Key Developments and Strategies, 2016-2019
  • Figure 4: Dominating Segments of the Global Clinical Biomarkers Market, 2019 and 2029
  • Figure 5: Global Clinical Biomarkers Market (by Product), 2019 and 2029
  • Figure 6: Global Clinical Biomarkers Market (by Clinical Area), 2019 and 2029
  • Figure 7: Global Clinical Biomarkers Market (by Technology), 2019 and 2029
  • Figure 8: Global Clinical Biomarkers Market (by End User), 2019 and 2029
  • Figure 9: Global Clinical Biomarkers Market (by Region), 2019 and 2029
  • Figure 2.1: Global Clinical Biomarkers Market Segmentation
  • Figure 3.1: Global Clinical Biomarkers Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Global Clinical Biomarkers Market, 2018 and 2029 ($Billion)
  • Figure 5.1: Number of Deaths by Top 18 Infectious Diseases, 2015
  • Figure 5.2: Number of Deaths (in Million) by Different Forms of Cancer, 2018
  • Figure 6.1: Share of Key Developments and Strategies, 2016-2019
  • Figure 6.2: Synergistic Activities Share (by Company), 2016 - 2019
  • Figure 6.3: Product Approval Share (by Company), 2016 -2019
  • Figure 6.4: Product Launches and Upgrades Share (by Company), 2016 -2019
  • Figure 6.5: Mergers and Acquisitions Share (by Company), 2016 -2019
  • Figure 6.6: Market Share Analysis for the Global Clinical Biomarkers Market, 2018
  • Figure 6.7: Growth Share Matrix for Global Clinical Biomarkers Market (by Company), 2018
  • Figure 7.1: Global Clinical Biomarkers Market (by Type), 2018-2029 ($Billion)
  • Figure 7.2: Global Clinical Biomarkers Market for Diagnostic Biomarkers, 2018-2029 ($Billion)
  • Figure 7.3: Global Clinical Biomarkers Market for Predictive Biomarkers, 2018-2029 ($Billion)
  • Figure 7.4: Global Clinical Biomarkers for Prognostic Biomarkers, 2018-2029 ($Billion)
  • Figure 8.1: Global Clinical Biomarkers Market (by Clinical Area), 2018-2029 ($Billion)
  • Figure 8.2: Global Clinical Biomarkers Market for Cancer Biomarkers, 2018-2029 ($Billion)
  • Figure 8.3: Global Clinical Biomarkers Market for Breast Cancer Biomarkers, 2018-2029 ($Billion)
  • Figure 8.4: Global Clinical Biomarkers Market for Lung Cancer Biomarkers, 2018-2029 ($Billion)
  • Figure 8.5: Global Clinical Biomarkers Market for Colorectal Cancer Biomarkers, 2018-2029 ($Billion)
  • Figure 8.6: Global Clinical Biomarkers Market for Prostate Cancer Biomarkers, 2018-2029 ($Billion)
  • Figure 8.7: Global Clinical Biomarkers Market for Cardiac Biomarkers, 2018-2029 ($Billion)
  • Figure 8.8: Global Clinical Biomarkers Market for Neurological Biomarkers, 2018-2029 ($Billion)
  • Figure 8.9: Global Clinical Biomarkers Market for Infectious Disease Biomarkers, 2018-2029 ($Billion)
  • Figure 8.10: Global Clinical Biomarkers Market for Immunological Biomarkers, 2018-2029 ($Billion)
  • Figure 8.11: Global Clinical Biomarkers Market for Non-Invasive Prenatal Testing, 2018-2029 ($Billion)
  • Figure 8.12: Global Clinical Biomarkers Market for Other Clinical Areas, 2018-2029 ($Billion)
  • Figure 9.1: Global Clinical Biomarkers Market for Real Time PCR, 2018-2029 ($Billion)
  • Figure 9.2: Global Clinical Biomarkers Market for ELISA, 2018-2029 ($Billion)
  • Figure 9.3: Global Clinical Biomarkers Market for IHC, 2018-2029 ($Billion)
  • Figure 9.4: Global Clinical Biomarkers Market for NGS, 2018-2029 ($Billion)
  • Figure 9.5: Global Clinical Biomarkers Market for Other Technologies, 2018-2029 ($Billion)
  • Figure 10.1: Global Clinical Biomarkers Market (by End User)
  • Figure 10.2: Global Clinical Biomarkers Market (by End User), 2018-2029 ($Billion)
  • Figure 10.3: Global Clinical Biomarkers Market for Research and Academic Laboratories, 2018-2029 ($Billion)
  • Figure 10.4: Global Clinical Biomarkers Market for Biopharmaceutical and Biotech Companies, 2018-2029 ($Billion)
  • Figure 10.5: Global Clinical Biomarkers Market for Diagnostic Centres, 2018-2029 ($Billion)
  • Figure 10.6: Global Clinical Biomarkers Market for Other End Users, 2018-2029 ($Billion)
  • Figure 11.1: Global Clinical Biomarkers Market (by Region), 2019 and 2029 ($Billion)
  • Figure 11.2: Global Clinical Biomarkers Market (by Region), 2018-2029 ($Billion)
  • Figure 11.3: Global Clinical Biomarkers Market Share (by Region), 2018 ($Billion)
  • Figure 11.4: Global Clinical Biomarkers Market Share (by Region), 2029 ($Billion)
  • Figure 11.5: North America Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.6: North America Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
  • Figure 11.7: North America: Market Dynamics
  • Figure 11.8: The U.S. Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.9: Canada Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.10: Europe Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.11: Europe: Market Dynamics
  • Figure 11.12: Europe Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
  • Figure 11.13: Germany Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.14: U.K. Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.15: France Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.16: Italy Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11 17: Spain Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.18: Rest-of-Europe Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.19: Asia-Pacific Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.20: APAC: Market Dynamics
  • Figure 11.21: APAC Global Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
  • Figure 11.22: China Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.23: Japan Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.24: India Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.25: Australia Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.26: Singapore Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.27: Rest-of-Asia Pacific Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.28: Latin America Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.29: Latin America: Market Dynamics
  • Figure 11.30: Latin America Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
  • Figure 11.31: Brazil Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.32: Mexico Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.33: Rest-of-Latin America Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 11.34: RoW Clinical Biomarkers Market, 2018-2029 ($Billion)
  • Figure 12.1: Total Number of Companies Profiled
  • Figure 12.2: Abbott Laboratories: Overall Product Portfolio
  • Figure 12.3: Abbott Laboratories: Overall Financials, 2016-2018
  • Figure 12.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
  • Figure 12.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
  • Figure 12.6: Abbott Laboratories: Revenue (by Region), 2016-2018
  • Figure 12.7: Abbott Laboratories: R&D Expenditure, 2016-2018
  • Figure 12.8: Abbott Laboratories: SWOT Analysis
  • Figure 12.9: Agilent Technologies, Inc.: Overall Product Portfolio
  • Figure 12.10: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 12.11: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.12: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.13: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.14: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 12.15: ALCEDIAG: Overall Product Portfolio
  • Figure 12.16: ALCEDIAG: SWOT Analysis
  • Figure 12.17: Becton, Dickinson and Company: Overall Product Portfolio
  • Figure 12.18: Becton, Dickinson and Company: Overall Financials, 2017-2019
  • Figure 12.19: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019
  • Figure 12.20: Becton, Dickinson and Company: Revenue (by Sub-Segment - BD Life Sciences), 2017-2019
  • Figure 12.21: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
  • Figure 12.22: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
  • Figure 12.23: Becton, Dickinson and Company: SWOT Analysis
  • Figure 12.24: bioMerieux S.A.: Overall Product Portfolio
  • Figure 12.25: bioMerieux S.A.: Overall Financials, 2016-2018
  • Figure 12.26: bioMerieux S.A.: Revenue (by Segment), 2016-2018
  • Figure 12.27: bioMerieux S.A.: Revenue (by Region), 2016-2018
  • Figure 12.28: bioMerieux S.A.: R&D Expenditure, 2016-2018
  • Figure 12.29: bioMerieux S.A.: SWOT Analysis
  • Figure 12.30: Bio-Rad Laboratories, Inc: Overall Product Portfolio
  • Figure 12.31: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
  • Figure 12.32: Bio-Rad Laboratories, Inc.: Sales (by Segment), 2016-2018
  • Figure 12.33: Bio-Rad Laboratories, Inc.: Sales (by Region), 2016-2018
  • Figure 12.34: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
  • Figure 12.35: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 12.36: CENTOGENE N.V.: Overall Product Portfolio
  • Figure 12.37: CENTOGENE N.V.: Overall Financials, 2016-2018
  • Figure 12.38: CENTOGENE N.V.: Sales (by Segment), 2016-2018
  • Figure 12.39: CENTOGENE N.V.: Sales (by Region), 2016-2018
  • Figure 12.40: CENTOGENE N.V.: R&D Expenditure, 2016-2018
  • Figure 12.41: CENTOGENE N.V.: SWOT Analysis
  • Figure 12.42: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
  • Figure 12.43: F. Hoffmann-La Roche Ltd.: Overall Financials, 2016-2018
  • Figure 12.44: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2016-2018
  • Figure 12.45: F. Hoffmann-La Roche Ltd.: Sales (by Region), 2016-2018
  • Figure 12.46: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2016-2018
  • Figure 12.47: F. Hoffmann-La Roche Ltd.: SWOT Analysis
  • Figure 12.48: Enzo Biochem Inc.: Overall Product Portfolio
  • Figure 12.49: Enzo Biochem Inc.: Overall Financials, 2017-2019
  • Figure 12.50: Enzo Biochem Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.51: Enzo Biochem Inc.: Revenue (by Region), 2017-2019
  • Figure 12.52: Enzo Biochem Inc.: R&D Expenditure, 2017-2019
  • Figure 12.53: Enzo Biochem Inc.: SWOT Analysis
  • Figure 12.54: Hologic, Inc.: Overall Product Portfolio
  • Figure 12.55: Hologic, Inc.: Overall Financials, 2017-2019
  • Figure 12.56: Hologic, Inc.: Sales (by Segment), 2017-2019
  • Figure 12.57: Hologic, Inc.: Sales (by Region), 2017-2019
  • Figure 12.58: Hologic, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.59: Hamilton, Inc.: SWOT Analysis
  • Figure 12.60: Illumina, Inc: Overall Product Portfolio
  • Figure 12.61: Illumina, Inc.: Overall Financials, 2016-2018
  • Figure 12.62: Illumina, Inc.: Sales (by Segment), 2016-2018
  • Figure 12.63: Illumina, Inc.: Sales (by Region), 2016-2018
  • Figure 12.64: Illumina, Inc.: R&D Expenditure, 2016-2018
  • Figure 12.65: Illumina, Inc.: SWOT Analysis
  • Figure 12.66: Myriad Genetics, Inc.: Overall Product Portfolio
  • Figure 12.67: Myriad Genetics, Inc.: Overall Financials, 2017-2019
  • Figure 12.68: Myriad Genetics, Inc.: Sales (by Segment), 2017-2019
  • Figure 12.69: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.70: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 12.71: Quest Diagnostics Incorporated, Inc.: Overall Product Portfolio
  • Figure 12.72: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
  • Figure 12.73: Quest Diagnostics Incorporated.: Sales (by Segment), 2016-2018
  • Figure 12.74: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 12.75: QIAGEN N.V.: Overall Product Portfolio
  • Figure 12.76: QIAGEN N.V.: Overall Financials, 2016-2018
  • Figure 12.77: QIAGEN N.V.: Revenue (by Segment), 2016-2018
  • Figure 12.78: QIAGEN N.V.: Revenue (by Region), 2016-2018
  • Figure 12.79: QIAGEN N.V.: R&D Expenditure, 2016-2018
  • Figure 12.80: QIAGEN N.V.: SWOT Analysis
  • Figure 12.81: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 12.82: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
  • Figure 12.83: Thermo Fisher Scientific Inc: Sales (by Segment), 2016-2018
  • Figure 12.84: Thermo Fisher Scientific Inc.: Sales (by Region), 2016-2018
  • Figure 12.85: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
  • Figure 12.86: Thermo Fisher Scientific Inc.: SWOT Analysis